Interv Akut Kardiol. 2013;12(1):21-26

Optimized current antitachycardia programing of implantable cardioverter-defibrillators

Lukáš Krýže, Domenico Grieco, Josef Kautzner, Kamil Sedláček
Klinika kardiologie IKEM, Praha

Previous randomized controlled trials have shown that the implantable cardioverter–defibrillator (ICD) provides a significant mortality reduction

in patients at high risk of sudden cardiac death. Despite technological advances, ICD patients still face a high incidence of therapies

delivered for causes other that life-threatening ventricular arrhythmias. These unnecessary and inappropriate therapies, apart from being

painful and psychologically disturbing, may also result in fatal tachyarrhythmias. A high proportion of unnecessary and inappropriate shocks

is the result of a conservative and aggressive ICD programming. In this review we focus on recent evidences related to ICD programming

and reduction of unnecessary/inappropriate therapies and propose ways to rational and evidence-based ICD programming of ICDs that

can effectively reduce the number of unnecessary and/or inappropriate therapies and maximize benefit from this highly successful therapy.

Keywords: implantable cardioverter–defibrillator, programming, inappropriate therapy

Published: February 21, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krýže L, Grieco D, Kautzner J, Sedláček K. Optimized current antitachycardia programing of implantable cardioverter-defibrillators. Interv Akut Kardiol. 2013;12(1):21-26.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bardy GH, Lee KL, Mark DB, Poole JE, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators: Amiodarone or implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237. Go to original source... Go to PubMed...
    2. Moss AJ, Hall WJ, Cannom DS, et al. Multicenter Automatic Defibrillator Implantation Trial Investigators: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-1940. Go to original source... Go to PubMed...
    3. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G, for the Multicenter Unsustained Tachycardia Trial Investigators: A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341: 1882-1890. Go to original source... Go to PubMed...
    4. Moss AJ, Zareba W, Hall WJ, et al. the Multicenter Automatic Defibrillator Implantation Trial II Investigators: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883. Go to original source... Go to PubMed...
    5. Connolly S, Gent M, Roberts R, et al. Canadian Implantable Defibrillator Study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101:1297-1302. Go to original source... Go to PubMed...
    6. Kuck K-H, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable cardioverter defibrillator in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748-754. Go to original source... Go to PubMed...
    7. Germano JJ, Reynolds M, Essebag V, Josephson ME. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? Am J Cardiol. 2006; 97(8): 1255-1261. Go to original source... Go to PubMed...
    8. Daubert JP, Zareba W, Cannom DS, et al. MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008; 51(14): 1357-1365. Go to original source... Go to PubMed...
    9. Van Rees JB, Borleffs CJW, De Bie MK, et al. Inappropriate implantable cardioverter-defibrillator shocks: Incidence, predictors, and impact on mortality. J Am Coll Cardiol 2011; 57: 556-562. Go to original source... Go to PubMed...
    10. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008; 359: 1009-1017. Go to original source... Go to PubMed...
    11. Pedersen SS, van den Broek KC, Sears SF Jr. Psychological intervention following implantation of an implantable defibrillator: a review and future recommendations. Pacing Clin Electrophysiol 2007; 30: 1546-1554. Go to original source... Go to PubMed...
    12. Magyar-Russell G, Thombs BD, Cai JX, et al. The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: a systematic review. J Psychosom Res 2011; 71: 223-231. Go to original source... Go to PubMed...
    13. Ellenbogen KA, Levine JH, Berger RD, et al. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation. 2006; 113(6): 776-782. Go to original source... Go to PubMed...
    14. Wathen MS, Sweeney MO, DeGroot PJ, Stark AJ, Koehler JL, Chisner MB, Machado C, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 2001; 104: 796-801. Go to original source... Go to PubMed...
    15. Wathen MS, DeGroot PJ, Sweeney MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 2004; 110: 2591-2596. Go to original source... Go to PubMed...
    16. Wilkoff BL, Williamson BD, Stern RS, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: Results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 2008; 52: 541-550. Go to original source... Go to PubMed...
    17. Schwab JO, Gasparini M, Lunati M, et al. Avoid delivering therapies for nonsustained fast ventricular tachyarrhythmia in patients with implantable cardioverter/defibrillator: the ADVANCE III Trial. J Cardiovasc Electrophysiol. 2009;20:663-666. Go to original source... Go to PubMed...
    18. Schuger C, Daubert JP, Brown MW, et al. Multicenter automatic defibrillator implantation trial: reduce inappropriate therapy (MADIT-RIT): background, rationale, and clinical protocol. Ann Noninvasive Electrocardiol. 2012; 17(3): 176-185. Go to original source... Go to PubMed...
    19. Moss AJ, Schuger C, Beck CA, et al. the MADIT-RIT Trial Investigators. Reduction in Inappropriate Therapy and Mortality through ICD Programming. N Engl J Med. 2012 Nov 6.
    20. Russo AM, Nayak H, Verdino R, et al. Implantable cardioverter defibrillator events in patients with asymptomatic nonsustained ventricular tachycardia: Is device implantation justified? Pacing Clin Electrophysiol 2003; 26: 2289-2295. Go to original source... Go to PubMed...
    21. Clementy N, Pierre B, Lallemand B, et al. Long-term follow-up on high-rate cut-off programming for implantable cardioverter defibrillators in primary prevention patients with left ventricular systolic dysfunction. Europace. 2012; 14(7): 968-974. Go to original source... Go to PubMed...
    22. Mansour F, Khairy P. Programming ICDs in the Modern Era beyond Out-of-the Box Settings. Pacing Clin Electrophysiol. 2011; 34(4): 506-520. Go to original source... Go to PubMed...
    23. Swerdlow CD, Chen PS, Kass RM, Allard JR, Peter CT. Discrimination of ventricular tachycardia from sinus tachycardia and atrial fibrillation in a tiered-therapy cardioverter-defibrillator. J Am Coll Cardiol 1994; 23: 1342-1355. Go to original source... Go to PubMed...
    24. Brugada J, Mont L, Figueiredo M, Valentino M, Matas M, Navarro-Lopez F. Enhanced detection criteria in implantable defibrillators. J Cardiovasc Electrophysiol 1998; 9: 261-268. Go to original source... Go to PubMed...
    25. Duru F, Bauersfeld U, Rahn-Schonbeck M, Candinas R. Morphology discriminator feature for enhanced ventricular tachycardia discrimination in implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2000; 23: 1365-1374. Go to original source... Go to PubMed...
    26. Theuns DA, Klootwijk AP, Goedhart DM, Jordaens LJ. Prevention of inappropriate therapy in implantable cardioverter-defibrillators: Results of a prospective, randomized study of tachyarrhythmia detection algorithms. J Am Coll Cardiol 2004; 44: 2362-2367. Go to original source... Go to PubMed...
    27. Klein RC, Raitt MH, Wilkoff BL, et al. Analysis of im- plantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol 2003;14: 940-948. Go to original source... Go to PubMed...
    28. Kuhlkamp V, Dornberger V, Mewis C, et al. Clinical experi- ence with the new detection algorithms for atrial fibrillation of a defibrillator with dual chamber sensing and pacing. J Cardiovasc Electrophysiol 1999; 10: 905-915. Go to original source... Go to PubMed...
    29. Deisenhofer I, Kolb C, Ndrepepa G, et al. Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies? A randomized, prospective study. J Cardiovasc Electrophysiol 2001; 12: 134-142. Go to original source... Go to PubMed...
    30. Olshansky B, Day JD, Moore S, et al. Is dual-chamber programming inferior to single-chamber programming in an implantable cardioverter-defibrillator? Results of the INTRIN- SIC RV (Inhibition of Unnecessary RV Pacing With AVSH in ICDs) Study. Circulation 2007; 115: 9-16. Go to original source... Go to PubMed...
    31. Friedman PA, McClelland RL, Bamlet WR, et al. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: The detect supraventricular tachycardia study. Circulation 2006; 113: 2871-2879. Go to original source... Go to PubMed...
    32. Wilkoff BL, Cook JR, Epstein AE, et al. Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002; 288(24): 3115-3123. Go to original source... Go to PubMed...
    33. Dewland TA, Pellegrini CN, Wang Y, et al. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. J Am Coll Cardiol 2011; 58: 1007-1013. Go to original source... Go to PubMed...
    34. Dorian P, Philippon F, Thibault B, et al. Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. Heart Rhythm 2004; 1: 540-547. Go to original source... Go to PubMed...
    35. Bansch D, Castrucci M, Bocker D, Breithardt G, Block M. Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: Incidence, prediction and significance. J Am Coll Cardiol 2000; 36: 557-565. Go to original source... Go to PubMed...
    36. Sadoul N, Mletzko R, Anselme F, et al. Incidence and clinical relevance of slow ventricular tachycardia in implantable cardioverter-defibrillator recipients: An international multicenter prospective study. Circulation 2005; 112: 946-953. Go to original source... Go to PubMed...
    37. Arya A, Haghjoo M, Emkanjoo Z, Dehghani MR, Sadr-Ameli MA. Does the rate of inappropriate therapy differ in implantable cardioverter-defibrillators from different manufacturers? J Interv Card Electrophysiol 2006; 17: 59-63. Go to original source... Go to PubMed...
    38. Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: Results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol 2006; 48: 330-339. Go to original source... Go to PubMed...
    39. Gulizia MM, Piraino L, Scherillo M, et al. A randomized study to compare ramp versus burst antitachycardia pacing therapies to treat fast ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators: The PITAGORA ICD trial. Circ Arrhythm Electrophysiol 2009; 2: 146-153. Go to original source... Go to PubMed...
    40. Santini M, Lunati M, Defaye P, et al. Prospective multicentre randomized trial of fast ventricular tachycardia termination by prolonged versus conventional anti-tachyarrhythmia burst pacing in implantable cardioverter-defibrillator patients-Atp DeliVery for pAiNless ICD therapy (ADVANCE-D) Trial results. J Interv Card Electrophysiol. 2010; 27(2): 127-135. Go to original source... Go to PubMed...
    41. Schoels W, Steinhaus D, Johnson WB, et al. EnTrust Clinical Study Investigators. Optimizing implantable cardioverter-defibrillator treatment of rapid ventricular tachycardia: antitachycardia pacing therapy during charging. Heart Rhythm. 2007; 4(7): 879-885. Go to original source... Go to PubMed...
    42. Sivagangabalan G, Eshoo S, Eipper VE, Thiagalingam A, Kovoor P. Discriminatory therapy for very fast ventricular tachycardia in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2008; 31: 1095-1099. Go to original source... Go to PubMed...
    43. Schaer BA, Koller MT, Sticherling C, Altmann D, Joerg L, Osswald S. Longevity of implantable cardioverter-defibrillators, influencing factors, and comparison to industry-projected longevity. Heart Rhythm 2009; 6: 1737-1743. Go to original source... Go to PubMed...
    44. Piekarz J, Rydlewska A, Majewski J, Lelakowski J. Antitachyarrhythmic interventions of implantable cardioverter-defibrillator in primary and secondary sudden cardiac death prevention patients. Pol Merkur Lekarski. 2012; 32(192): 368-373. Go to PubMed...
    45. Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol 2004; 15: 1002-1009. Go to original source... Go to PubMed...
    46. Backenkohler U, Erdogan A, Steen-Mueller MK, et al. Long-term incidence of malignant ventricular arrhythmia and shock therapy in patients with primary defibrillator implantation does not differ from event rates in patients treated for survived cardiac arrest. J Cardiovasc Electrophysiol 2005; 16:478-482. Go to original source... Go to PubMed...
    47. Gasparini M, Anselme F, Clementy J, et al. BIVentricular versus right ventricular antitachycardia pacing to terminate ventricular tachyarrhythmias in patients receiving cardiac resynchronization therapy: The ADVANCE CRT-D Trial. Am Heart J 2010; 159: 1116-1123, e1112. Go to original source... Go to PubMed...
    48. Smith T, Theuns DA, Caliskan K, Jordaens L. Long-term follow-up of prophylactic implantable cardioverter-defibrillator-only therapy: comparison of ischemic and nonischemic heart disease. Clin Cardiol. 2011; 34(12): 761-767. Go to original source... Go to PubMed...
    49. Streitner F, Kuschyk J, Dietrich C, et al. Comparison of ventricular tachyarrhythmia characteristics in patients with idiopathic dilated or ischemic cardiomyopathy and defibrillators implanted for primary prevention. Clin Cardiol. 2011; 34(10): 604-609. Go to original source... Go to PubMed...
    50. Verma A, Sarak B, Kaplan AJ, et al. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy. Pacing Clin Electrophysiol. 2010; 33(3): 320-329. Go to original source... Go to PubMed...
    51. Fries R, Heisel A, Kalweit G, Jung J, Schieffer H. Antitachycardia pacing in patients with implantable cardioverter defibrillators: How many attempts are useful? Pacing Clin Electrophysiol 1997; 20: 198-202. Go to original source... Go to PubMed...
    52. Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart. 2009; 95(9): 709-714. Go to original source... Go to PubMed...
    53. Kim SS, Knight BP. Defibrillator therapies in hypertrophic cardiomyopathy: Too many swings at bad pitches? J Cardiovasc Electrophysiol 2007; 18: 488-489. Go to original source... Go to PubMed...
    54. Przybylski A, Małecka L, Pytkowski M, et al. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy - dilemmas and difficulties. Kardiol Pol. 2005; 63(4): 391-397. Go to PubMed...
    55. Tavernier R, Gevaert S, De Sutter J, et al. Long term results of cardioverter-defibrillator implantation in patients with right ventricular dysplasia and malignant ventricular tachyarrhythmias. Heart 2001; 85:53-56. Go to original source... Go to PubMed...
    56. Roguin A, Bomma CS, Nasir K, et al. Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2004; 43: 1843-1852. Go to original source... Go to PubMed...
    57. Bordachar P, Reuter S, Garrigue S, et al. Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J, 2004; 25: 879-884. Go to original source... Go to PubMed...
    58. Kharazi A, Emkanjoo Z, Alizadeh A, Nikoo MH, Jorat MV, Sadr- Ameli MA. Mid-term follow-up of patients with Brugada syndrome following a cardioverter defibrillator implantation: a single center experience. Indian Pacing Electrophysiol J; 2007; 7: 33-39.
    59. Sacher F, Probst V, Iesaka Y, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation. 2006; 114: 2317-2324. Go to original source... Go to PubMed...
    60. Sarkozy A, Boussy T, Kourgiannides G, et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J, 2007; 28: 334-344. Go to original source... Go to PubMed...
    61. Veltmann C, Kuschyk J, Schimpf R, et al. Prevention of inappropriate ICD shocks in patients with Brugada syndrome. Clin Res Cardiol. 2010; 99(1): 37-44. Go to original source... Go to PubMed...
    62. Viskin S. Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J Cardiovasc Electrophysiol. 2000; 11(5): 593-600. Go to original source... Go to PubMed...
    63. Viskin S, Fish R. Prevention of ventricular arrhythmias in the congenital long QT syndrome. Curr Cardiol Rep. 2000; 2(6): 492-497. Go to original source... Go to PubMed...
    64. Swerdlow CD. Supraventricular tachycardia-ventricular tachycardia discrimination algorithms in implantable cardioverter defibrillators: State-of-the-art review. J Cardiovasc Electrophysiol 2001; 12: 606-612. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.